Clinical Trials for Other Solid Tumor

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the combination of amivantamab, an EGFR-MET bispecific antibody, and docetaxel in patients with metastatic NSCLC lacking oncogenic driver mutations, who have progressed on platinum-based chemotherapy and immune checkpoint inhibitors. The study focuses on determining the recommended Phase 2 dose and assessing the treatment's efficacy.

ClinicalTrials.gov ID: NCT06532032

A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adult patients with advanced ALK-rearranged NSCLC, including both treatment-naïve and those progressed on second-generation ALK TKIs, to assess the combination of lorlatinib, a third-generation ALK TKI, and ramucirumab, an anti-VEGFR2 monoclonal antibody.

ClinicalTrials.gov ID: NCT06007937

PROMISE-005: a Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic Breast or Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The PROMISE-005 trial evaluates the efficacy of stereotactic body radiotherapy (SBRT) combined with standard care versus standard care alone in patients aged 18 or older with 1-5 oligometastases from metastatic breast cancer or non-small cell lung cancer, including those with targetable molecular alterations who have previously progressed on tyrosine kinase inhibitors. Participants receive SBRT to all detectable metastatic sites alongside ongoing systemic treatment, with an emphasis on improving progression-free survival.

ClinicalTrials.gov ID: NCT03808337

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the combination of durvalumab, an anti-PD-L1 monoclonal antibody, and tremelimumab, an anti-CTLA-4 monoclonal antibody, with platinum-based chemotherapy in treating patients with stage IV NSCLC who are infected with HIV, HBV, or HCV.

ClinicalTrials.gov ID: NCT04499053

Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets patients with stage III NSCLC who experience oligoprogressive or polyprogressive disease post-chemoradiation and anti-PD-L1 therapy, evaluating the combination of local consolidative therapy (LCT) and durvalumab, an anti-PD-L1 immunotherapy, with the addition of systemic chemotherapy in polyprogressive cases.

ClinicalTrials.gov ID: NCT04892953

A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets adult patients with advanced NSCLC harboring ALK, ROS1, and RET gene fusions who have progressed on at least one prior FDA-approved TKI, assessing the combination of the investigational bispecific antibody amivantamab, which targets EGFR and MET receptors, with current TKI therapies to overcome acquired resistance.

ClinicalTrials.gov ID: NCT05845671

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial evaluates Trastuzumab Deruxtecan, a HER2-targeted antibody-drug conjugate, as a first-line treatment for patients with unresectable, locally advanced, or metastatic non-squamous NSCLC with HER2 exon 19 or 20 mutations, comparing its efficacy and safety to the standard regimen of cisplatin or carboplatin, pembrolizumab, and pemetrexed. Participants must be treatment-naïve and have an ECOG performance status of 0-1.

ClinicalTrials.gov ID: NCT05048797

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the subcutaneous administration of amivantamab, a bispecific antibody targeting EGFR and MET, in patients with advanced or metastatic NSCLC with specific EGFR mutations, with treatment regimens including monotherapy and combinations with agents like lazertinib, carboplatin, and pemetrexed. Participants include treatment-naïve patients, those post-osimertinib, and prior amivantamab IV recipients, aiming to assess efficacy and safety, including transitioning patients from intravenous to subcutaneous formulations.

ClinicalTrials.gov ID: NCT05498428

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination with the PARP Inhibitor Olaparib in Patients with KRAS G12C Mutated Advanced Solid Tumors, with a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates the combination of adagrasib, a KRAS G12C inhibitor, with the PARP inhibitor olaparib in adult patients with KRAS G12C mutated advanced solid tumors, focusing on pancreatic, breast, uterine/epithelial ovarian cancers, and NSCLC with additional KEAP1 mutations.

ClinicalTrials.gov ID: NCT06130254

PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial examines the efficacy of romiplostim, a thrombopoietin receptor agonist, in adult patients aged 18 and above with stage I-IV NSCLC, ovarian cancer, or breast cancer experiencing chemotherapy-induced thrombocytopenia during carboplatin-based regimens, aiming to maintain platelet levels for full-dose chemotherapy.

ClinicalTrials.gov ID: NCT03937154